The Top Line · Fierce Life Sciences
Patent expirations push biopharma industry toward a tougher 2026
·18 min·1 clip
Teva's expected decline is dramatic, shifting from a 4% increase to a 4% decrease, reversing CEO Richard Francis's three-year pivot to growth strategy.
As heard by us
A steady read on how patent cliffs are reshaping biopharma guidance.
The segment uses the top 25 biopharma companies' fourth quarter earnings to show how quickly a familiar growth story can turn brittle once blockbuster drugs start losing patent protection.
Why you'd press play
See which big drugmakers are heading into a tougher 2026.
Listen to the show on